<DOC>
	<DOCNO>NCT00005798</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat woman breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine long term remission rate measure disease free survival woman breast cancer treat cyclophosphamide , thiotepa , carboplatin follow autologous hematopoietic stem cell transplantation . II . Determine safety efficacy combination chemotherapy regimen patient population . OUTLINE : Peripheral blood stem cell ( PBSC ) collect . Patients sequentially receive cyclophosphamide IV 1 hour , thiotepa IV 1 hour , carboplatin IV 1 hour day -6 -4 . PBSC reinfused day 0 . Patients follow 3 month , 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : At least 40 patient 4-9 positive lymph node least 50 patient 10 positive lymph node accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage II great 3 positive axillary lymph node follow standard induction chemotherapy , well surgery and/or radiation clinically indicated Stage III follow standard induction chemotherapy anthracycline base regimen , surgery and/or radiation clinically indicate Inflammatory carcinoma follow standard induction chemotherapy anthracycline base regimen , surgery and/or radiation clinically indicated Stage IV metastatic disease demonstrate complete response anthracycline contain regimen , evidence disease surgery radiation Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 64 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 2.5 time upper limit normal No history severe hepatic dysfunction Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No evidence severe cardiac dysfunction Ejection fraction least 50 % MUGA No major heart disease Essential hypertension control medication allow Pulmonary : DLCO least 50 % normal No symptomatic obstructive restrictive pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychosocial disorder would preclude study compliance No concurrent active infection No insulin dependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No significant skin breakdown tumor disease HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior total dose doxorubicin daunorubicin le 450 mg/m2 unless endometrial biopsy show less grade 2 drug effect Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent nitroglycerin preparation angina pectoris No concurrent antiarrhythmic drug major ventricular dysrrhythmias</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>